ARDX · Ardelyx, Inc.
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Cash & Investments | $281.8M | Q2 2026 | — |
| GTN adjustment percentage | 34% | Three Months Ended June 30, 2026 filing | — |
| IBSRELA product sales, net | $86.24M | Three Months Ended June 30, 2026 filing | +32.6% |
|
|
|||
| XPHOZAH product sales, net | $31.89M | Three Months Ended June 30, 2026 filing | +27.4% |
|
|
|||
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ARDX
this stock
Ardelyx, Inc.
|
$817.34M | -43.7% | -93.8% | — | 11.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$129.29B | +12.5% | +46.2% | 29.7 | 1.8% |
|
MRNA
Moderna, Inc.
|
$89.83B | +663.0% | +4.3% | — | 7.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$76.86B | -3.3% | +20.8% | 18.5 | 2.1% |
|
CSLLY
Csl Ltd
|
$61.83B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ARDX | -1.8% | -8.4% | -47.9% | -4.1% | -43.7% |
| SPY | +1.2% | +1.9% | +9.9% | +2.1% | +14.2% |
| vs SPY | -3.0% | -10.3% | -57.8% | -6.2% | -57.9% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.